Business Description
UCB SA
ISIN : BE0003739530
Share Class Description:
STU:UNC: Ordinary SharesTotal Employee Number:
10,117Description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.09 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | 0.87 | |||||
Interest Coverage | 21.78 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 5.62 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.1 | |||||
3-Year EBITDA Growth Rate | 30.2 | |||||
3-Year EPS without NRI Growth Rate | 45.9 | |||||
3-Year FCF Growth Rate | 35.2 | |||||
3-Year Book Growth Rate | 6.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.97 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.28 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.17 | |||||
9-Day RSI | 45.86 | |||||
14-Day RSI | 48.91 | |||||
3-1 Month Momentum % | -2.08 | |||||
6-1 Month Momentum % | 2.73 | |||||
12-1 Month Momentum % | 59.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 1.04 | |||||
Cash Ratio | 0.56 | |||||
Days Inventory | 254.64 | |||||
Days Sales Outstanding | 65.82 | |||||
Days Payable | 291.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.56 | |||||
Dividend Payout Ratio | 0.17 | |||||
3-Year Dividend Growth Rate | 2.3 | |||||
Forward Dividend Yield % | 0.56 | |||||
5-Year Yield-on-Cost % | 0.63 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 1.75 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.29 | |||||
Operating Margin % | 25.89 | |||||
Net Margin % | 20.13 | |||||
EBITDA Margin % | 33.29 | |||||
FCF Margin % | 23.8 | |||||
OCF Margin % | 29.6 | |||||
ROE % | 15.28 | |||||
ROA % | 8.87 | |||||
ROIC % | 13.06 | |||||
3-Year ROIIC % | -234.53 | |||||
ROC (Joel Greenblatt) % | 107.26 | |||||
ROCE % | 14.33 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 31.7 | |||||
Forward PE Ratio | 24.57 | |||||
PE Ratio without NRI | 31.79 | |||||
Shiller PE Ratio | 38.52 | |||||
Price-to-Owner-Earnings | 22.09 | |||||
PEG Ratio | 2.54 | |||||
PS Ratio | 6.38 | |||||
PB Ratio | 4.46 | |||||
Price-to-Tangible-Book | 20.79 | |||||
Price-to-Free-Cash-Flow | 26.82 | |||||
Price-to-Operating-Cash-Flow | 21.57 | |||||
EV-to-EBIT | 24.73 | |||||
EV-to-Forward-EBIT | 22.65 | |||||
EV-to-EBITDA | 18.71 | |||||
EV-to-Forward-EBITDA | 17.29 | |||||
EV-to-Revenue | 6.23 | |||||
EV-to-Forward-Revenue | 5.85 | |||||
EV-to-FCF | 26.71 | |||||
Price-to-GF-Value | 1.2 | |||||
Price-to-Projected-FCF | 2.86 | |||||
Price-to-Median-PS-Value | 2.81 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.54 | |||||
Price-to-Graham-Number | 5.42 | |||||
Earnings Yield (Greenblatt) % | 4.04 | |||||
FCF Yield % | 3.8 | |||||
Forward Rate of Return (Yacktman) % | 14.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
UCB SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7,741 | ||
| EPS (TTM) (€) | 8.03 | ||
| Beta | 0.367 | ||
| 3-Year Sharpe Ratio | 1.49 | ||
| 3-Year Sortino Ratio | 3.17 | ||
| Volatility % | 27.16 | ||
| 14-Day RSI | 48.91 | ||
| 14-Day ATR (€) | 6.961528 | ||
| 20-Day SMA (€) | 258.18 | ||
| 12-1 Month Momentum % | 59.46 | ||
| 52-Week Range (€) | 166.05 - 289.4 | ||
| Shares Outstanding (Mil) | 190.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
UCB SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
UCB SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-07-31 14:00 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 24 days | ||
| EUR 1.450000 Cash Dividend | 2026-05-04 | 230.90 (+0.00%) | ||
| General meeting for 2026 | 2026-04-30 11:00 | 225.10 (-1.36%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 14:00 | 269.80 (-0.66%) | ||
| Annual report for 2025 | 2026-02-26 | 269.80 (-0.66%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 269.80 (-0.66%) | ||
| KBC Life Sciences Conference | 2025-09-25 | 205.10 (+0.69%) | ||
| BofA - Global Healthcare Conference | 2025-09-24 | 205.20 (-0.48%) | ||
| JP Morgan - CEO Call series | 2025-09-18 | 203.40 (+0.00%) |
Show
Entries
UCB SA Frequently Asked Questions
What is UCB SA(STU:UNC)'s stock price today?
The current price of STU:UNC is €254.30. The 52 week high of STU:UNC is €289.40 and 52 week low is €166.05.
When is next earnings date of UCB SA(STU:UNC)?
The next earnings date of UCB SA(STU:UNC) is 2026-07-31 Est..
Does UCB SA(STU:UNC) pay dividends? If so, how much?
The Dividend Yield %  of UCB SA(STU:UNC) is 0.56% (As of Today), Highest Dividend Payout Ratio of UCB SA(STU:UNC) was 0.76. The lowest was 0.14. And the median was 0.2. The  Forward Dividend Yield % of UCB SA(STU:UNC) is 0.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on UCB SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers